查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179557

癌症幹細胞市場：按癌症類型、按應用分類：2021-2031 年全球機會分析和行業預測

Cancer Stem Cells Market By Cancer Forms, By Application : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

從 2022 年到 2031 年，全球癌症幹細胞市場預計將以 10.0% 的複合年增長率增長，從 2021 年的 10.552 億美元增長到 2031 年的 27.118 億美元。

癌症是一種對人類生命構成極大威脅的暫時性疾病。 已經開發了多種治療癌症的方法，包括手術、化學療法、放射療法和靶向療法。 得益於這些治療，女性的癌症發病率已經穩定，男性的癌症發病率略有下降，同期癌症死亡率也有所下降。 常規癌症治療僅限於特定的惡性腫瘤，轉移、異質性、化療和放療耐藥、逃避免疫監視是導致癌症治療失敗的主要原因。我來了。 這些失敗可能是由於癌症幹細胞的特性所致。 癌症幹細胞具有早期阻滯和形成新腫瘤的特性，可能導致癌症的擴散和復發、多藥耐藥、放射耐藥等。 因此，癌症幹細胞作為一種有效的癌症治療方法具有最大的前景。

幹細胞移植是一種複雜且有風險的臨床過程，例如用於診斷惡性腫瘤的放射療法。 癌症幹細胞 (CSC) 和正常乾細胞共享許多基本的生物信號通路。 當正常乾細胞的微環境發生負面改變時，它們可以變成 CSC，從而產生成熟的腫瘤組織。 移植的干細胞在移植前培養過程中可能會暴露於可能改變基因組表達和未來表型的環境因素。 如果長時間培養，幹細胞更容易成為癌細胞。 這些因素預計將在預測期內阻礙癌症幹細胞市場的增長。

腫瘤幹細胞是癌細胞復發和轉移的原因之一。 此外，癌症幹細胞對大多數化學療法都有抵抗力。 此外，癌症幹細胞在一定程度上促成了腫瘤細胞的異質性和復發。 為了實現腫瘤的完全消退，必須解決癌症幹細胞問題。 最近的免疫治療發展在癌症治療中顯示出有希望的結果，這也適用於癌症幹細胞。 存在於不同腫瘤中的癌症幹細胞表達免疫學標記並顯示特定的免疫特性。 利用這一特性，可以針對腫瘤微環境中的癌症幹細胞進行免疫治療。 近年來，腫瘤幹細胞在技術進步和研究開發方面備受關注。 癌症幹細胞越來越成為基於樹突細胞 (DC) 的疫苗、適應性 T 細胞、溶瘤病毒、免疫檢查點抑製劑和聯合療法的目標。

COVID-19 大流行帶來了許多不確定性，導致世界各地的各種企業停滯不前，導致嚴重的經濟損失。 COVID-19 的爆發對癌症幹細胞市場的增長產生了重大影響。 全球癌症患者數量的增加增加了對有效癌症幹細胞療法的需求。 癌症幹細胞研究人員以及各政府機構正在大力投資細胞療法的研發活動，以滿足 COVID-19 大流行期間對癌細胞療法不斷增長的需求。 例如，在 COVID-19 大流行期間，將研究幹細胞在抵抗 COVID-19 大流行中的適用性。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析
  • 監管準則
  • 價值鏈分析
  • 市場份額分析
  • 關鍵法規分析
  • 專利情況

第 4 章癌症幹細胞市場：按癌症類型分類

  • 概覽
    • 市場規模和預測
  • 乳房
    • 主要市場趨勢、增長因素和機遇
    • 各地區的市場規模和預測
    • 市場分析：按國家/地區分類
  • 血液
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 肺
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 大腦
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 大腸
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 胰腺
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 膀胱
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 肝臟
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章癌症幹細胞市場：按應用

  • 概覽
    • 市場規模和預測
  • 開發癌症幹細胞
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 幹細胞治療癌症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章癌症幹細胞市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按癌症類型
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按癌症類型
    • 歐洲市場規模和預測：按應用分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 英國
      • 法國
      • 西班牙
      • 意大利
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太地區按癌症類型劃分的市場規模和預測
    • 亞太地區的市場規模和預測：按應用分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳大利亞
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按癌症類型
    • LAMEA 市場規模和預測：按應用分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 阿聯酋
      • 南非
      • LAMEA 的其餘部分

第七章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第八章公司簡介

  • Thermo Fisher Scientific Inc.
  • AbbVie Inc.
  • Miltenyi Biotec
  • STEMCELL Technologies Inc.
  • Merck KGaA
  • Stemline Therapeutics, Inc.
  • MacroGenics, Inc.
  • Bionomics
  • FUJIFILM Irvine Scientific.
  • Lineage Cell Therapeutics, Inc.
Product Code: A08105

The global cancer stem cells market is envisioned to garner $2,711.8 million by 2031, growing from $1,055.2 million in 2021 at a CAGR of 10.0% from 2022 to 2031.

Cancers are time-related illnesses that pose a major threat to human life. For the treatment of cancer, a variety of methods have been developed, including surgery, chemo, radiation, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males, and the death rate from cancer has also decreased over the same period. Traditional cancer treatments, which only work for certain types of malignant tumors, metastasis, heterogeneity, as well as resistance to chemotherapy, radiotherapy, and avoiding immunological surveillance are the primary causes of cancer treatment failures. The traits of cancer stem cells could be the cause of all these failures. Due to their capacity to stop in the early phase, which results in the formation of fresh tumors, cancer stem cells can lead to cancer spread, cancer relapse, multidrug resistance, and radiation resistance. Cancer stem cells may therefore be considered of as the most promising cancer effective treatments.

The clinical procedures involved in stem cell transplantation are complex and high risk, including radiation therapy that is used to diagnose malignancy. Cancer stem cells (CSCs) and regular stem cells share many fundamental biologicals signaling pathways. Normal stem cells may become CSCs when their microenvironment changes negatively, which then causes the creation of the complete tumor tissue. While in culture prior to transplantation, transplanted stem cells may be exposed to environmental factors that could alter their genomic expression and future phenotype. Stem cells are more likely to become cancerous cells with increased culture time. These factors are predicted to hamper the cancer stem cells market growth in forecast time period.

Cancer stem cells are one of the causes of cancer cell relapse and metastasis. They are resistant to the majority of chemotherapeutic treatments. Additionally, cancer stem cell contributes to tumor cell heterogeneity and recurrent illness to some extent. Cancer stem cells must be addressed if total tumor regression is to be achieved. Recent developments in immunotherapies have demonstrated encouraging results in the treatment of cancer, which are also applicable to cancer stem cells. Cancer stem cells in different tumors express immunological markers and show certain immune traits, which can be exploited in immunotherapies to target cancer stem cells in the tumor microenvironment. Cancer stem cells have recently gained huge traction when it comes to technological advancements as well as research & development (R&D) initiatives. Cancer stem cells are increasingly being targeted using dendritic cell (DC)-based vaccines, adaptive T-cells, oncolytic viruses, immune checkpoint inhibitors, and combination treatments.

The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. The COVID-19 outbreak caused a significant effect on the cancer stem cell market growth. The rise in cancer cases globally is increasing the need for efficacious cancer stem cell therapies. Cancer stem cell researchers along with various government bodies are massively investing in Research and Development activities for cell-based therapies to cater to the rising demand for cancer cell therapies during the COVID-19 pandemic. For instance, during the COVID-19 pandemic, the use of stem cell applicability for resistance to the COVID-19 pandemic is researched.

The key players profiled in this report include: AdnaGen GmbH, Advanced Cell Diagnostics, Inc., AVIVA Biosciences Corporation, Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Rarecells USA, Inc. and Silicon Biosystems, S.p.A.

Key Market Segments

By Cancer Forms

  • Breast
  • Blood
  • Lung
  • Brain
  • Colorectal
  • Pancreatic
  • Bladder
  • Liver
  • Others

By Application

  • Trageted Cancerous Stem Cells
  • Stem Cell-based cancer Therapy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Thermo Fisher Scientific Inc.
    • AbbVie Inc.
    • Miltenyi Biotec
    • STEMCELL Technologies Inc.
    • Merck KGaA
    • Stemline Therapeutics, Inc.
    • MacroGenics, Inc.
    • Bionomics
    • FUJIFILM Irvine Scientific.
    • Lineage Cell Therapeutics, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Regulatory Guidelines
  • 3.8.Value Chain Analysis
  • 3.9.Market Share Analysis
  • 3.10.Key Regulation Analysis
  • 3.11.Patent Landscape

CHAPTER 4: CANCER STEM CELLS MARKET, BY CANCER FORMS

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Breast
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Blood
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Lung
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Brain
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Colorectal
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country
  • 4.7 Pancreatic
    • 4.7.1 Key market trends, growth factors and opportunities
    • 4.7.2 Market size and forecast, by region
    • 4.7.3 Market analysis by country
  • 4.8 Bladder
    • 4.8.1 Key market trends, growth factors and opportunities
    • 4.8.2 Market size and forecast, by region
    • 4.8.3 Market analysis by country
  • 4.9 Liver
    • 4.9.1 Key market trends, growth factors and opportunities
    • 4.9.2 Market size and forecast, by region
    • 4.9.3 Market analysis by country
  • 5.0 Others
    • 5.0.1 Key market trends, growth factors and opportunities
    • 5.0.2 Market size and forecast, by region
    • 5.0.3 Market analysis by country

CHAPTER 5: CANCER STEM CELLS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Trageted Cancerous Stem Cells
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Stem Cell-based cancer Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: CANCER STEM CELLS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Cancer Forms
    • 6.2.3 North America Market size and forecast, by Application
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Cancer Forms
      • 6.2.4.1.2 Market size and forecast, by Application
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Cancer Forms
      • 6.2.4.2.2 Market size and forecast, by Application
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Cancer Forms
      • 6.2.4.3.2 Market size and forecast, by Application
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Cancer Forms
    • 6.3.3 Europe Market size and forecast, by Application
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Cancer Forms
      • 6.3.4.1.2 Market size and forecast, by Application
      • 6.3.4.2 United Kingdom
      • 6.3.4.2.1 Market size and forecast, by Cancer Forms
      • 6.3.4.2.2 Market size and forecast, by Application
      • 6.3.4.3 France
      • 6.3.4.3.1 Market size and forecast, by Cancer Forms
      • 6.3.4.3.2 Market size and forecast, by Application
      • 6.3.4.4 Spain
      • 6.3.4.4.1 Market size and forecast, by Cancer Forms
      • 6.3.4.4.2 Market size and forecast, by Application
      • 6.3.4.5 Italy
      • 6.3.4.5.1 Market size and forecast, by Cancer Forms
      • 6.3.4.5.2 Market size and forecast, by Application
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Cancer Forms
      • 6.3.4.6.2 Market size and forecast, by Application
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Cancer Forms
    • 6.4.3 Asia-Pacific Market size and forecast, by Application
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Cancer Forms
      • 6.4.4.1.2 Market size and forecast, by Application
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Cancer Forms
      • 6.4.4.2.2 Market size and forecast, by Application
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Cancer Forms
      • 6.4.4.3.2 Market size and forecast, by Application
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Cancer Forms
      • 6.4.4.4.2 Market size and forecast, by Application
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Cancer Forms
      • 6.4.4.5.2 Market size and forecast, by Application
      • 6.4.4.6 Rest Of Asia Pacific
      • 6.4.4.6.1 Market size and forecast, by Cancer Forms
      • 6.4.4.6.2 Market size and forecast, by Application
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Cancer Forms
    • 6.5.3 LAMEA Market size and forecast, by Application
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Cancer Forms
      • 6.5.4.1.2 Market size and forecast, by Application
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Cancer Forms
      • 6.5.4.2.2 Market size and forecast, by Application
      • 6.5.4.3 UAE
      • 6.5.4.3.1 Market size and forecast, by Cancer Forms
      • 6.5.4.3.2 Market size and forecast, by Application
      • 6.5.4.4 South Africa
      • 6.5.4.4.1 Market size and forecast, by Cancer Forms
      • 6.5.4.4.2 Market size and forecast, by Application
      • 6.5.4.5 Rest of LAMEA
      • 6.5.4.5.1 Market size and forecast, by Cancer Forms
      • 6.5.4.5.2 Market size and forecast, by Application

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Thermo Fisher Scientific Inc.
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 AbbVie Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Miltenyi Biotec
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 STEMCELL Technologies Inc.
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Merck KGaA
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Stemline Therapeutics, Inc.
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 MacroGenics, Inc.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Bionomics
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 FUJIFILM Irvine Scientific.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Lineage Cell Therapeutics, Inc.
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 2. CANCER STEM CELLS MARKET SIZE, FOR BREAST, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. CANCER STEM CELLS MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. CANCER STEM CELLS MARKET SIZE, FOR BLOOD, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. CANCER STEM CELLS MARKET FOR BLOOD, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. CANCER STEM CELLS MARKET SIZE, FOR LUNG, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. CANCER STEM CELLS MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. CANCER STEM CELLS MARKET SIZE, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. CANCER STEM CELLS MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. CANCER STEM CELLS MARKET SIZE, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. CANCER STEM CELLS MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. CANCER STEM CELLS MARKET SIZE, FOR PANCREATIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. CANCER STEM CELLS MARKET FOR PANCREATIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. CANCER STEM CELLS MARKET SIZE, FOR BLADDER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. CANCER STEM CELLS MARKET FOR BLADDER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. CANCER STEM CELLS MARKET SIZE, FOR LIVER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. CANCER STEM CELLS MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. CANCER STEM CELLS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. CANCER STEM CELLS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 20. GLOBAL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 21. CANCER STEM CELLS MARKET SIZE, FOR TRAGETED CANCEROUS STEM CELLS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. CANCER STEM CELLS MARKET FOR TRAGETED CANCEROUS STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. CANCER STEM CELLS MARKET SIZE, FOR STEM CELL-BASED CANCER THERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. CANCER STEM CELLS MARKET FOR STEM CELL-BASED CANCER THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 25. CANCER STEM CELLS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. U.S. CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 30. U.S. CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 31. CANADA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 32. CANADA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 33. MEXICO CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 34. MEXICO CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 35. EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 36. EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 37. EUROPE CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 38. GERMANY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 39. GERMANY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 40. UNITED KINGDOM CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 41. UNITED KINGDOM CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 42. FRANCE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 43. FRANCE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 46. ITALY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 47. ITALY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. CHINA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 54. CHINA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 57. INDIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 58. INDIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 59. SOUTH KOREA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 60. SOUTH KOREA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 63. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 64. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 65. LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 66. LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 67. LAMEA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 68. BRAZIL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 69. BRAZIL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 70. SAUDI ARABIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 71. SAUDI ARABIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 72. UAE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 73. UAE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 74. SOUTH AFRICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 75. SOUTH AFRICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 76. REST OF LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
  • TABLE 77. REST OF LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 78.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 79.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 80.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 81.THERMO FISHER SCIENTIFIC INC.: NET SALES,
  • TABLE 82.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 83.ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 84.ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 85.ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 86.ABBVIE INC.: NET SALES,
  • TABLE 87.ABBVIE INC.: KEY STRATERGIES
  • TABLE 88.MILTENYI BIOTEC: COMPANY SNAPSHOT
  • TABLE 89.MILTENYI BIOTEC: OPERATING SEGMENTS
  • TABLE 90.MILTENYI BIOTEC: PRODUCT PORTFOLIO
  • TABLE 91.MILTENYI BIOTEC: NET SALES,
  • TABLE 92.MILTENYI BIOTEC: KEY STRATERGIES
  • TABLE 93.STEMCELL TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 94.STEMCELL TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 95.STEMCELL TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 96.STEMCELL TECHNOLOGIES INC.: NET SALES,
  • TABLE 97.STEMCELL TECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 98.MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 99.MERCK KGAA: OPERATING SEGMENTS
  • TABLE 100.MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 101.MERCK KGAA: NET SALES,
  • TABLE 102.MERCK KGAA: KEY STRATERGIES
  • TABLE 103.STEMLINE THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 104.STEMLINE THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 105.STEMLINE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 106.STEMLINE THERAPEUTICS, INC.: NET SALES,
  • TABLE 107.STEMLINE THERAPEUTICS, INC.: KEY STRATERGIES
  • TABLE 108.MACROGENICS, INC.: COMPANY SNAPSHOT
  • TABLE 109.MACROGENICS, INC.: OPERATING SEGMENTS
  • TABLE 110.MACROGENICS, INC.: PRODUCT PORTFOLIO
  • TABLE 111.MACROGENICS, INC.: NET SALES,
  • TABLE 112.MACROGENICS, INC.: KEY STRATERGIES
  • TABLE 113.BIONOMICS: COMPANY SNAPSHOT
  • TABLE 114.BIONOMICS: OPERATING SEGMENTS
  • TABLE 115.BIONOMICS: PRODUCT PORTFOLIO
  • TABLE 116.BIONOMICS: NET SALES,
  • TABLE 117.BIONOMICS: KEY STRATERGIES
  • TABLE 118.FUJIFILM IRVINE SCIENTIFIC.: COMPANY SNAPSHOT
  • TABLE 119.FUJIFILM IRVINE SCIENTIFIC.: OPERATING SEGMENTS
  • TABLE 120.FUJIFILM IRVINE SCIENTIFIC.: PRODUCT PORTFOLIO
  • TABLE 121.FUJIFILM IRVINE SCIENTIFIC.: NET SALES,
  • TABLE 122.FUJIFILM IRVINE SCIENTIFIC.: KEY STRATERGIES
  • TABLE 123.LINEAGE CELL THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 124.LINEAGE CELL THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 125.LINEAGE CELL THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 126.LINEAGE CELL THERAPEUTICS, INC.: NET SALES,
  • TABLE 127.LINEAGE CELL THERAPEUTICS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CANCER STEM CELLS MARKET SEGMENTATION
  • FIGURE 2.CANCER STEM CELLS MARKET,2021-2031
  • FIGURE 3.CANCER STEM CELLS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CANCER STEM CELLS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.REGULATORY GUIDELINES
  • FIGURE 13.VALUE CHAIN ANALYSIS
  • FIGURE 14.MARKET SHARE ANALYSIS
  • FIGURE 15.KEY REGULATION ANALYSIS
  • FIGURE 16.PATENT ANALYSIS BY COMPANY
  • FIGURE 17.PATENT ANALYSIS BY COUNTRY
  • FIGURE 18.CANCER STEM CELLS MARKET,BY CANCER FORMS,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF BREAST CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF BLOOD CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF LUNG CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF BRAIN CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF COLORECTAL CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF PANCREATIC CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF BLADDER CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF LIVER CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 28.CANCER STEM CELLS MARKET,BY APPLICATION,2021(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF TRAGETED CANCEROUS STEM CELLS CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF STEM CELL-BASED CANCER THERAPY CANCER STEM CELLS MARKET,2021-2031(%)
  • FIGURE 31.CANCER STEM CELLS MARKET BY REGION,2021
  • FIGURE 32.U.S. CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 33.CANADA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 34.MEXICO CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 35.GERMANY CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 36.UNITED KINGDOM CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 37.FRANCE CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 38.SPAIN CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 39.ITALY CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF EUROPE CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 41.CHINA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 42.JAPAN CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 43.INDIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH KOREA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 45.AUSTRALIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 46.REST OF ASIA PACIFIC CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 47.BRAZIL CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 48.SAUDI ARABIA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 49.UAE CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 50.SOUTH AFRICA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 51.REST OF LAMEA CANCER STEM CELLS MARKET,2021-2031($MILLION)
  • FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 55.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 56.COMPETITIVE DASHBOARD
  • FIGURE 57.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 58.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
  • FIGURE 59.ABBVIE INC..: NET SALES ,($MILLION)
  • FIGURE 60.MILTENYI BIOTEC.: NET SALES ,($MILLION)
  • FIGURE 61.STEMCELL TECHNOLOGIES INC..: NET SALES ,($MILLION)
  • FIGURE 62.MERCK KGAA.: NET SALES ,($MILLION)
  • FIGURE 63.STEMLINE THERAPEUTICS, INC..: NET SALES ,($MILLION)
  • FIGURE 64.MACROGENICS, INC..: NET SALES ,($MILLION)
  • FIGURE 65.BIONOMICS.: NET SALES ,($MILLION)
  • FIGURE 66.FUJIFILM IRVINE SCIENTIFIC..: NET SALES ,($MILLION)
  • FIGURE 67.LINEAGE CELL THERAPEUTICS, INC..: NET SALES ,($MILLION)